Anti-Human CD262 Recombinant Antibody(Drozitumab)

Product Information

Catalog Number	YR1229
Product Name	Anti-Human CD262 Recombinant Antibody(Drozitumab)
Molecular Name	Drozitumab
Alias	Anti-CD262 Recombinant Antibody, Research Grade Drozitumab
CAS Number	912628-39-8
Target	CD262[Homo sapiens]
Isotype	IgG1 Lambda
Clonity	Monoclonal
Source	CHO Cells
Size	1mg, 5mg
Concentration	1mg/ml
Purity	>95% as determined by SDS-PAGE
Applications	ELISA, FCM, IP, FuncS, IF, Neut
Buffer	PBS, pH7.5
Background	Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.
Storage	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Note	This product is for research use only.

Cat#	Product Name	Species	Host	Applications	Size	Price